Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (Weighted Average) (2016 - 2025)

Neurocrine Biosciences' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $99.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 0.9% year-over-year to $99.5 million; the TTM value through Dec 2025 reached $99.5 million, down 0.9%, while the annual FY2025 figure was $99.5 million, 0.9% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $99.5 million in Q4 2025 per NBIX's latest filing, roughly flat from $99.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $101.1 million in Q3 2024 to a low of $94.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $97.5 million, with a median of $97.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 3.49% in 2024, then fell 1.79% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $94.6 million in 2021, then rose by 1.27% to $95.8 million in 2022, then increased by 1.98% to $97.7 million in 2023, then rose by 2.76% to $100.4 million in 2024, then fell by 0.9% to $99.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Shares Outstanding (Weighted Average) are $99.5 million (Q4 2025), $99.3 million (Q3 2025), and $99.0 million (Q2 2025).